Refer	ence	 	

GENETICALLY ENGINEERED FVIII

I spoke to He expressed great surprise at the report in 'The Times' about Biogen.

The 'Cloner' at Biogen is a whizz-kid ex who left to go to Biogen, taking his

As recently as 2 months ago! was in contact with him at which time he appeared totally unfamiliar with FVIII and its properties and, indeed, agreed to have a meeting with him to see what assistance the Professor's unit could give Brogen in the first step towards genetically engineering FVIII ie the purification of FVIIIC.

thinks that Genentech may be ahead of the field. They have access to highly purified FVIIIC produced by the Royal Free team Apparently Genentech now owns the RF method and Speywood has signed a collaboration agreement with Genentech in relation to genetic engineering of FVIII.

will be ready to answer questions at the CBLA meeting on 3 December but feels unable to predict the timescale of developments in this field.

I also spoke to who feels that nothing has happened which would significantly change the picture since the Project Steering Group first considered genetic engineering and that, provided there are no unacceptable delays in redeveloping BPL, economic appraisal would still be valid. He considers that problems of large scale manufacture and purification of genetically engineered material are likely to be so great that production by this method is likely to be expensive. In the case, say, of albumin, the costs might be of the same order as for blood fractionation. Since albumin derived from blood does not transmit hepatitis and since albumin genetically engineered in bacteria could contain various bacteria-derived undesirables, the blood-derived albumin could still be the better option.

MED SEB Room 1025A HANH

30 November 1982

STOP PRESS

has just telephoned. Biogen itself apparently denies that it is near producing FVIII - it only wishes it were! The story in 'The Times' was completely garbled and wrong, apparently. However, I think there is a valuable spin-off from the story in that it should prompt the CBLA into examining its proposed investment in the light of current developments in genetic engineering. I feel that the sooner this exercise is done the better in order to reassure our financial colleagues and the Treasury - otherwise each new reported 'break-through' will have them rushing to cancel the cheques!